Marker Therapeutics Inc (MRKR)

[Epicare]

Mixed feeling for AACR presentation. I believe we have at least a good news if it is not an "exciting" one. However, I also feel some reservations.

1. AACR is different from ASCO in the sense that most attendees are lab researchers rather than clinicians. People at AACR care more about molecular mechanisms than clinical outcomes. That is why most meaningful clinical trials presented at ASCO to draw clinicians attention. So it is really pitty this data was not presented at ASCO meeting a couple of months ago.

2. I am puzzling at that the presenter is a very junior oncologist just graduated from his fellowship a couple of years ago. I understand it is a clinical trial data which shall be presented by a clinician rather than company CEO or a senior scientist like Ann Leen. But normally you have a senior team leader to present something really exciting at the Plenary session.
3. Is the conference call immediately after the presentation because of most investors and clinicians not going to AACR to get the news spread and attract the market attention?

Regardless since I believe the science and know its advantages, I grabbed 2K shares today for long holding.